A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Clinical trial NCT06086197 · RECRUITING

Trial details

NCT number: NCT06086197
Sponsor: Zhejiang Cancer Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma Recurrent Diffuse Large B Cell Lymphoma Refractory

Start date: 2023-10-01
Primary completion: 2025-10-01
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.